October 14, 2005 -- Pfizer and Nektar Therapeutics won a recommendation from the European advisory panel for Exubera, the inhaled form of insulin; MedImmune and Medarex filed to move a lupus drug into clinical trials; Regeneration Technologies recalled the tissue harvested by Biomedical Tissue Services and took a $3 million charge; OraSure will seek approval for an over-the-counter version of its oral fluid HIV test; Voyager reset the terms of its IPO; Electro-Optical Sciences lowered the talk price on its upcoming IPO; Indian pharma Cipla will make a generic version of Roche’s Tamiflu; BioCryst hit a new 52-week high; and Celgene was up 9% on a Merrill upgrade. The Centient Biotech 200 gained 42 points to end the day at 3666, an increase of 1.16%. More details...
